Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week. Parabilis Medicines secured $670 million when it ...

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

The Big 12 Conference wants to sanction Texas Tech for its intention on playing Brendan Sorsby this upcoming season, and it is asking a court in the Northern District of Texas to pave the way for its ...

First, let's start out by taking a closer look at Parabilis. The company launched in 2015, built on many years of research out of Greg Verdine's Harvard University lab. He was a co-founder and chief ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study No dose-limiting toxicities, serious adverse ...

Sorsby's proposed punishment of a two-game suspension for gambling on college football, instead of permanent ineligibility per NCAA rules, was accepted by a district court judge. Ron Jenkins / Getty ...

Texas Attorney General Ken Paxton (R), a candidate for Senate, is warning schools across the Big 12 Conference that the state would consider suing any institution that sanctions Texas Tech over a ...

The Big 12 Conference filed a complaint in federal court seeking a declaratory judgment that would allow the league to enforce its bylaws and potentially sanction member Texas Tech should the school ...

The Big 12 Conference filed a federal lawsuit on June 15, 2026, in the Northern District of Texas. The suit targets Texas Tech University and the Texas Attorney General. This legal move aims to ...

No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management Additional ...

As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a ...